The Name on the Label: FDA Duties That Belong to the Brand, Not the Co-Packer

does a brand that owns no facility have to register anything with the FDA?

No. Under 21 CFR 1.225, as codified in Cornell Law School's Legal Information Institute text, the registration duty attaches to the owner, operator, or agent in charge of a domestic or foreign facility that manufactures, processes, packs, or holds food for U.S. consumption. A virtual supplement brand that designs formulas, contracts a manufacturer, and sells through its own storefront owns no such facility, so it carries no registration obligation of its own under the Bioterrorism Act/FSMA scheme — the duty sits with whoever physically touches the product.

Most brands in this niche operate exactly that way. You approve a formula, a contract manufacturer produces it, a 3PL ships it, and a merchant of record handles the transaction, none of which requires you to file anything with FDA. That structure is legal and common; it is also why so many operators mistake "we don't register" for "we carry no FDA exposure." The two are not the same claim.

Owning no facility removes exactly one obligation: facility registration. Everything downstream of that — what the label says, who FDA contacts when a customer reports harm, whether the finished batch actually matches the formula on file — still lands on the name printed on the bottle. The rest of this page works through each of those non-delegable duties in turn.

who registers under the food facility rules, the co-packer, the 3PL, or you?

Both the co-packer and the 3PL register, and in most brand structures, you do not. The exemptions carved out in 21 CFR 1.226 cover farms, retail food establishments, restaurants, nonprofit food establishments, fishing vessels and USDA-regulated facilities, a list Cornell LII's text shows omits contract manufacturers and third-party logistics warehouses entirely. Because neither role fits an exemption, both must register as facilities that manufacture, process, pack or hold product for U.S. consumption.

The exception is a brand that holds its own inventory. Rent a warehouse, receive finished goods there, and ship from it yourself, and you become a holding facility under the same rule your co-packer already answers to. A registration certificate is not evidence of quality; it says a mailing address exists on file, a distinction worth separating from what a FDA-registered vs GMP-certified badge actually signals on a manufacturer's marketing page.

when is the biennial renewal window, and what breaks if your manufacturer misses it?

The renewal window runs October 1 through December 31 of each even-numbered year, which makes the next one October 1 to December 31, 2026, per the renewal cadence set out in 21 CFR 1.230. That section requires initial registration before a facility begins to manufacture, process, pack or hold food, then renewal on that fixed two-year cadence — not a rolling anniversary date tied to when the facility first registered.

A registration that lapses in that window does not sit in a grace period. Under 21 CFR 1.241, a facility that fails to renew is treated as having failed to register under section 415 of the FD&C Act, itself a prohibited act under section 301(dd) exposing the firm to injunction and criminal prosecution. Food from an unregistered foreign facility is held under the subpart I import procedures, meaning your manufacturer's paperwork lapse can stop your own product at the border.

You do not file the renewal. You do have standing to ask for proof it happened, and calendar Q4 of every even year as the date to ask for it. A manufacturer that cannot produce a current registration number in November 2026 is a manufacturer worth replacing before you find out the hard way.

what does being the responsible person on the label actually obligate you to do?

It obligates you to receive and forward serious adverse event reports. Under 21 U.S.C. 379aa-1, the "responsible person" is the manufacturer, packer, or distributor whose name appears on the label, and that person must submit any serious adverse event report it receives to FDA within 15 business days of receipt, a duty triggered by the name on the bottle, not by who manufactured what's inside it.

A serious adverse event is defined narrowly: death, a life-threatening experience, inpatient hospitalization, persistent or significant disability, a birth defect, or an event requiring intervention to prevent one of those outcomes. Records of each report must be kept for six years and produced to FDA inspectors on request. Filing the report is not, on its own, an admission that the product caused the event; the statute says so directly.

Most brands find out what this means the first time a support inbox receives something that reads like a hospitalization, not a complaint. Building the intake and escalation path before that email arrives is the actual work; the reporting duties and recall readiness that follow a harm claim rarely start with someone who already knows the 15-business-day clock exists.

why must the label carry a domestic address or phone number, and what arrives there?

Because without one, the product is misbranded. 21 U.S.C. 343(y) makes a dietary supplement misbranded unless its label bears a domestic address or domestic telephone number through which the responsible person can receive a serious adverse event report, the mechanism that makes the reporting duty in the previous section actually reachable by a consumer or a regulator.

21 CFR 101.5 governs the name-and-place-of-business statement more broadly: it must appear conspicuously, and where the named firm is not the actual manufacturer, it must be qualified with a phrase like "Manufactured for ___" or "Distributed by ___." The statement needs a street address, city, state and ZIP, though the street address can be dropped if the firm is listed in a current city or telephone directory, and 101.5(e) allows a principal place of business to stand in for the actual production site as long as that isn't misleading.

What arrives at that address is not fan mail. It is the serious adverse event report, the occasional attorney letter, and — for a foreign-run brand shipping into the US — the reason a domestic contact point has to exist at all even when nobody on the team lives there. Getting this line wrong is one of the more common failures a supplement label ships with, because a designer optimizing for panel space treats it as filler text rather than a legal requirement.

who is exposed when the manufacturer's cGMP records fail an inspection?

You are, not the contractor who produced the batch. FDA said as much in the preamble to the Part 111 final rule, published in the Federal Register at 72 FR 34752: a quality control operation performed by a contractor or third party "is no different than a quality control operation performed by your employees," and "if, during the course of an inspection, we find the requirements of this final rule were not followed, we will hold you, rather than the contractor or other third party, responsible."

This is where the niche's most common assumption breaks down. Plenty of operators treat a manufacturer's FDA registration, or a "GMP certified" badge on a sell sheet, as something close to a safety approval, proof the product has been checked and cleared. FDA's own language says otherwise on both counts: registration means the facility is on a list, and separately, under DSHEA, FDA "does not have the authority to approve dietary supplements before they are marketed" and "does not test dietary supplements before they are sold." Neither status substitutes for you knowing how your own product is made.

The same preamble states that a brand contracting out manufacture "has an obligation to know what and how manufacturing activities are performed" before releasing product for distribution, and that the term "you" in the cGMP rule "can refer to someone with whom you contract, but you are responsible for ensuring that the requirements are met, and to have documentation." Practically, that means specifications on file, batch records you can request, and a release decision you can defend, not just a badge on a manufacturer's sell sheet.

what is a new dietary ingredient notification, and whose job is it to file one?

A New Dietary Ingredient notification is the safety dossier FDA requires before a supplement containing an ingredient not sold in the US food supply before October 15, 1994 can enter commerce. Under 21 U.S.C. 350b, the manufacturer or distributor must submit that safety information at least 75 days before the product is introduced or delivered for introduction into interstate commerce; skip it, and the product is deemed adulterated under 21 U.S.C. 342(f).

The duty does not attach to every ingredient. It is waived where the supplement "contains only dietary ingredients which have been present in the food supply as an article used for food in a form in which the food has not been chemically altered," the grandfathered exemption that covers most common vitamins and minerals but rarely covers a novel extract, a new delivery form, or an ingredient your formulator sourced because a competitor doesn't have it yet.

FDA's NDI notification guidance is explicit that the requirement falls on "manufacturers and distributors," not solely on whoever supplies the raw ingredient. If your formula includes something a supplier calls proprietary or novel, the 75-day clock and the notification paperwork are your problem to solve before launch, regardless of what assurances the ingredient supplier gives you about its own compliance history.

what changes when the product is made overseas or shipped outside the US?

A foreign facility takes on an extra registration burden that a domestic one doesn't carry. In addition to the standard 21 CFR 1.225 registration, a foreign facility must supply the name, full address, phone and email of a US agent, plus a separate emergency contact, a requirement with no domestic equivalent, since a US-based facility is already reachable directly.

Every import shipment also needs Prior Notice under 21 CFR 1.279, confirmed for FDA review no less than 2 hours before arrival by road, 4 hours by rail or air, and 8 hours by water, submitted no more than 30 calendar days ahead through ABI/ACE/ITDS or 15 days via FDA PNSI. Importers separately carry risk-based Foreign Supplier Verification Program duties under 21 CFR Part 1 Subpart L, which sit on top of, not instead of, the manufacturer's own registration.

Landed cost is the part that moves fastest and needs the most frequent recheck. Tariff policy has shifted materially through 2026 — average effective rates, Section 122 and Section 301 tariffs, and country-specific rates have all moved within the year, so any specific figure printed on a reference page like this one should be treated as stale by the time you read it and confirmed against current guidance at time of purchase order.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Clickbank Affiliate Sign Up Free: Free Until Exactly Where, Peptide Sciences Affiliate Program Sign Up, Clickbank Create Affiliate Account: The Practical Version, ClickBank Sales Page Examples From Live Offers, What is a VSL?, and UTM parameter decoding guide. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.